About: Immunotherapies for Aging-Related Neurodegenerative Diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Creator	Iba, Michiyo Kim, Changyoun Kwon, Somin Masliah, Eliezer
Source	PMC
abstract	Neurological disorders such as Alzheimer’s disease (AD), Lewy body dementia (LBD), frontotemporal dementia (FTD), and vascular dementia (VCID) have no disease-modifying treatments to date and now constitute a dementia crisis that affects 5 million in the USA and over 50 million worldwide. The most common pathological hallmark of these age-related neurodegenerative diseases is the accumulation of specific proteins, including amyloid beta (Aβ), tau, α-synuclein (α-syn), TAR DNA-binding protein 43 (TDP43), and repeat-associated non-ATG (RAN) peptides, in the intra- and extracellular spaces of selected brain regions. Whereas it remains controversial whether these accumulations are pathogenic or merely a byproduct of disease, the majority of therapeutic research has focused on clearing protein aggregates. Immunotherapies have garnered particular attention for their ability to target specific protein strains and conformations as well as promote clearance. Immunotherapies can also be neuroprotective: by neutralizing extracellular protein aggregates, they reduce spread, synaptic damage, and neuroinflammation. This review will briefly examine the current state of research in immunotherapies against the 3 most commonly targeted proteins for age-related neurodegenerative disease: Aβ, tau, and α-syn. The discussion will then turn to combinatorial strategies that enhance the effects of immunotherapy against aggregating protein, followed by new potential targets of immunotherapy such as aging-related processes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13311-020-00853-2) contains supplementary material, which is available to authorized users.
has issue date	2020-04-28(xsd:dateTime)
bibo:doi	10.1007/s13311-020-00853-2
bibo:pmid	32347461
has license	no-cc
sha1sum (hex)	b934ab88a1e99ca95296f4c4cc76a776f70182c5
schema:url	https://doi.org/10.1007/s13311-020-00853-2
resource representing a document's title	Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
has PubMed Central identifier	PMC7222955
has PubMed identifier	32347461
schema:publication	Neurotherapeutics
resource representing a document's body	covid:b934ab88a1e99ca95296f4c4cc76a776f70182c5#body_text
is schema:about of	named entity 'immunotherapy' named entity 'clearing' named entity 'tau' named entity 'neuroinflammation' named entity 'amyloid beta' named entity 'turn' named entity 'proteins' named entity 'extracellular' named entity 'Neurodegenerative' covid:arg/b934ab88a1e99ca95296f4c4cc76a776f70182c5 named entity 'brain' named entity 'peptides' named entity 'protein' named entity 'potential' named entity 'Neurological disorders' named entity 'aggregates' named entity 'disease' named entity 'pathogenic' named entity 'enhance' named entity 'combinatorial' named entity 'damage' named entity 'effects' named entity 'dementia' named entity 'α-synuclein' named entity 'neurodegenerative diseases' named entity 'protein aggregates' named entity 'protein' named entity 'immunotherapies' named entity 'Immunotherapies' named entity 'aging-related' named entity 'amyloid beta' named entity 'peptides' named entity 'Aging-Related' named entity 'stem cell' named entity 'immune surveillance' named entity 'amyloid plaques' named entity 'microglia' named entity 'cell senescence' named entity 'phosphorylation' named entity 'Lewy body dementia' named entity 'single-chain antibodies' named entity 'peptides' named entity 'protein' named entity 'immunotherapy' named entity 'neurodegenerative process' named entity 'neurons' named entity 'Basel' named entity 'data set' named entity 'SNCA' named entity 'peptides' named entity 'extracellular' named entity 'microglia' named entity 'tubulin' named entity 'microtubule' named entity 'neurodegenerative' named entity 'Belgium' named entity 'vaccine' named entity 'passive diffusion' named entity 'catalyzes' named entity 'long-term' named entity 'antibody' named entity 'paired helical filaments' named entity 'amyloid-β' named entity 'PSP' named entity 'actively uptake' named entity 'neurodegenerative diseases' named entity 'NIA' named entity 'spinal muscular atrophy' named entity 'hyperphosphorylation' named entity 'biomarkers' named entity 'personalized medicine' named entity 'protein aggregate' named entity 'extracellular' named entity 'Switzerland' named entity 'Immunotherapies' named entity 'proteostasis' named entity 'CNS' named entity 'tauopathies'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software